BridgeBio Pharma, Inc.

NASDAQ:BBIO

Biotechnology

Healthcare
$78.01 +1.13%

+$0.75 today

Market cap
$15.20B
Beta
0.97
P/E (TTM)
-18.1
EPS (TTM)
-$3.73
52W Low $40.19High $84.94

Volume 3.55M

Average 2.49M

BBIO Cash & Equivalents

Cash on hand and highly liquid investments that can be converted to cash almost immediately.

BridgeBio Pharma, Inc.NASDAQ: BBIO

Cash & Equivalents · Q2 FY2026 · quarter ended Jun 2026

Cash & equivalents falls 9.5% from a year ago

Cash & equivalents stood at $677.91M at the end of Q2 FY2026, down 9.5% from a year earlier and down 23.0% from the prior quarter. Over 3 fiscal years it compounded at +14.8% a year.

Context

  • Cash & equivalents amounted to 55.7% of total assets at the end of Q2 FY2026, down 13.7 pp from a year earlier.
  • Cash & equivalents increased in 1 of the last 3 fiscal years.

What to watch

Whether cash & equivalents keeps falling in the next quarterly balance sheet after a -9.5% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterJun 2026
$677.91M-23.0% QoQ
Last fiscal yearDec 2025
$570.12M-16.3% YoY
Year agoJun 2025
$749.4M-9.5% since
Cash & Equivalents past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-9.5%——
1 year-16.3%——
3-year CAGR+14.8%——
5-year CAGR——
10-year CAGR——

Cash & Equivalents history

USD · from the balance sheet

Latest · FY2025
570.12M USD
Year-over-year change
-16.3%
4-year CAGR
+9.7%

Cash & Equivalents vs competitors

How BBIO compares with its peers on the latest reported figures

  • Peers report in different currencies, so cash & equivalents is compared through growth and share of total assets rather than absolute size.
  • Its year-over-year change of -9.5% is the 9th highest of 11, against a peer median of +32.7%.
  • Cash & equivalents amounts to 55.7% of total assets for BBIO, versus a peer median of 24.1%.
BBIO Competitors
Cash & Equivalents for BBIO and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
BMRNBioMarin Pharmaceutical Inc.Sep 2026$736.01B USD+58775.5%+21.9%6.4%
ALNYAlnylam Pharmaceuticals, Inc.Jun 2026$1.71B USD+53.4%+24.1%30.7%
PTCTPTC Therapeutics, Inc.Jun 2026$1.05B USD+3.2%+52.1%32.3%
ASNDAscendis Pharma A/SSep 2026€964.36M EUR+78.9%+11.5%39.7%
BBIOBridgeBio Pharma, Inc.Jun 2026$677.91M USD-9.5%+14.8%55.7%
SRRKScholar Rock Holding CorporationSep 2026$366.27M USD+27.7%+46.3%82.1%
IONSIonis Pharmaceuticals, Inc.Sep 2026$296.3M USD-12.4%+10.4%10.2%
DNLIDenali Therapeutics Inc.Jun 2026$201.53M USD+42.7%-2.0%17.4%
MAZEMaze Therapeutics, Inc.Mar 2026$198.77M USD-32.5%+23.7%47.4%
RAREUltragenyx Pharmaceutical Inc.Mar 2026$175M USD+37.7%+48.3%13.5%
TVTXTravere Therapeutics, Inc.Sep 2026$123.54M USD+11.4%+14.7%14.6%
Peer median (excluding BBIO) —+32.7%+22.8%24.1%

Competitors are the stored peer set for BBIO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents393.77M376.69M375.94M681.1M570.12M
Short-term Investments442.89M95.23M58.95M017.36M
Net Receivables19.75M17.08M1.75M4.72M139.44M
Inventory000026.75M
Other Current Assets177K37.93M27.65M3.83M0
Total Current Assets888.86M548.85M477.59M720.69M753.68M
Property, Plant & Equipment (Net)45.97M25.25M19.84M12.78M13.52M
Goodwill00000
Intangible Assets44.93M28.71M26.32M23.93M28.08M
Long-term Investments2.42M2.87M3.74M143.75M81.44M
Tax Assets00000
Other Non-current Assets30.61M17.36M18.88M18.2M(81.44M)
Total Non-current Assets123.93M74.18M68.79M198.65M41.59M
Total Assets1.01B623.04M546.38M919.34M936.03M
Account Payables11.88M11.56M10.66M9.62M36.23M
Short-term Debt000017.41M
Tax Payables00000
Deferred Revenue08.16M6.1M020.27M
Other Current Liabilities37.04M31.26M65.6M16.2M214.06M
Total Current Liabilities135.07M121.43M143.84M154.4M287.97M
Long-term Debt1.7B1.71B1.73B1.72B2.71B
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)000013.08M
Other Non-current Liabilities22.07M26.64M9.36M496.47M244K
Total Non-current Liabilities1.74B1.75B1.75B2.22B2.72B
Total Liabilities1.88B1.87B1.89B2.38B3.01B
Common Stock154K157K181K196K202K
Retained Earnings(1.44B)(1.92B)(2.56B)(3.1B)(3.82B)
Accumulated OCI(132K)(328K)31K8K12K
Other Stockholders Equity00000
Minority Interest4.84M9.69M11.72M10.29M(570K)
Total Equity(865.58M)(1.24B)(1.34B)(1.46B)(2.08B)
Total Debt1.73B1.72B1.74B1.73B2.73B
Net Debt1.33B1.35B1.36B1.05B2.16B

BridgeBio Pharma, Inc.

NASDAQ:BBIO

Intrinsic Alpha fair value

Locked

Current Price

$78.01

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.